

# Daniel P Petrylak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/557882/publications.pdf>

Version: 2024-02-01

55  
papers

14,796  
citations

159585

30  
h-index

155660

55  
g-index

56  
all docs

56  
docs citations

56  
times ranked

15081  
citing authors

#	ARTICLE	IF	CITATIONS
1	Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. <i>Journal of the National Cancer Institute</i> , 2022, 114, 310-313.	6.3	2
2	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 35-42.	1.9	5
3	Targeting prostate cancer with <i>Clostridium perfringens</i> enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 40, 102477.	3.3	5
4	Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. <i>European Journal of Cancer</i> , 2022, 160, 61-71.	2.8	29
5	Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3182-3192.	2.4	4
6	Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). <i>Journal of Clinical Oncology</i> , 2022, 40, 17-17.	1.6	62
7	Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1616-1622.	1.6	111
8	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021, 127, 435-444.	2.5	7
9	Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer. <i>Oncology</i> , 2021, 35, 166-168.	0.5	2
10	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1125-1135.	27.0	473
11	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , 2021, 27, 793-801.	30.7	56
12	CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC). <i>Journal of Clinical Oncology</i> , 2021, 39, 5044-5044.	1.6	11
13	Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 4539-4539.	1.6	9
14	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2474-2485.	1.6	250
15	Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01430.	1.6	3
16	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3291-3299.	2.4	22
17	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	10.7	61
18	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 916-924.	1.9	18

#	ARTICLE	IF	CITATIONS
19	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 1218-1230.	27.0	802
20	Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. <i>Bladder Cancer</i> , 2020, 6, 43-52.	0.4	2
21	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa003.	2.9	1
22	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , 2020, 126, 2597-2606.	4.1	39
23	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1041-1049.	1.6	159
24	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	10.7	193
25	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2974-2986.	1.6	643
26	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2592-2600.	1.6	404
27	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2961-2967.	1.6	13
28	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. <i>Targeted Oncology</i> , 2019, 14, 505-525.	3.6	40
29	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-410.	1.6	83
30	Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. <i>Lancet Oncology</i> , The, 2018, 19, 23-24.	10.7	7
31	Introduction to the Yale Precision Medicine Tumor Board. <i>Lancet Oncology</i> , The, 2018, 19, 19-20.	10.7	3
32	Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e469-e476.	1.9	16
33	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	1.6	155
34	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1579-1587.	1.6	97
35	Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1081-1088.	1.2	157
36	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	9.4	206

#	ARTICLE	IF	CITATIONS
37	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. <i>Cell</i> , 2018, 174, 1200-1215.e20.	28.9	96
38	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. <i>Clinical Cancer Research</i> , 2018, 24, 4662-4671.	7.0	27
39	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1015-1026.	27.0	2,677
40	Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. <i>Targeted Oncology</i> , 2017, 12, 401-412.	3.6	6
41	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2266-2277.	13.7	153
42	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 168-171.	1.9	48
43	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. <i>JAMA Oncology</i> , 2017, 3, 68.	7.1	33
44	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	4.9	93
45	From the Guest Editor. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 321.	2.0	1
46	A Patient With Pancytopenia, Intractable Epistaxis, and Metastatic Prostate Cancer: How Correct Diagnosis of Primary Hyperfibrinolysis Helps to Stop the Bleeding. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e545-e548.	1.9	6
47	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1909-1920.	13.7	3,077
48	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.	1.6	332
49	A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. <i>Cancer Cell</i> , 2015, 27, 223-239.	16.8	128
50	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 417-425.	10.7	137
51	New developments in the treatment of castration resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 555.	1.6	6
52	Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 137-147.	4.2	225
53	Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 760-768.	10.7	256
54	The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy. <i>Oncology</i> , 2013, 27, 1028, 1030.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 1513-1520.	27.0	3,344